Arcus Biosciences, Inc.
ANTIBODIES TO TIGIT

Last updated:

Abstract:

The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.

Status:
Application
Type:

Utility

Filling date:

1 Jun 2021

Issue date:

3 Mar 2022